WO2007104567A3 - Pegyliertes mutiertes clostridium botulinum toxin - Google Patents

Pegyliertes mutiertes clostridium botulinum toxin Download PDF

Info

Publication number
WO2007104567A3
WO2007104567A3 PCT/EP2007/002296 EP2007002296W WO2007104567A3 WO 2007104567 A3 WO2007104567 A3 WO 2007104567A3 EP 2007002296 W EP2007002296 W EP 2007002296W WO 2007104567 A3 WO2007104567 A3 WO 2007104567A3
Authority
WO
WIPO (PCT)
Prior art keywords
chain
botulinum toxin
clostridium botulinum
terminus
tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/002296
Other languages
English (en)
French (fr)
Other versions
WO2007104567A2 (de
Inventor
Juergen Frevert
Volker Specht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotecon Therapeutics GmbH
Original Assignee
Biotecon Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002638862A priority Critical patent/CA2638862A1/en
Priority to AT07723281T priority patent/ATE443078T1/de
Priority to HK09108510.5A priority patent/HK1128929B/xx
Priority to US12/282,601 priority patent/US8003601B2/en
Priority to DE502007001546T priority patent/DE502007001546D1/de
Priority to BRPI0708907-4A priority patent/BRPI0708907A2/pt
Priority to CN200780015607.5A priority patent/CN101432296B/zh
Priority to AU2007224669A priority patent/AU2007224669B2/en
Priority to MX2008011495A priority patent/MX2008011495A/es
Priority to KR1020087023540A priority patent/KR101454273B1/ko
Priority to EP07723281A priority patent/EP1994048B1/de
Priority to JP2008558725A priority patent/JP5232021B2/ja
Application filed by Biotecon Therapeutics GmbH filed Critical Biotecon Therapeutics GmbH
Publication of WO2007104567A2 publication Critical patent/WO2007104567A2/de
Publication of WO2007104567A3 publication Critical patent/WO2007104567A3/de
Priority to IL193777A priority patent/IL193777A/en
Anticipated expiration legal-status Critical
Priority to US13/185,925 priority patent/US8298550B2/en
Priority to US13/624,493 priority patent/US8912140B2/en
Priority to US14/538,132 priority patent/US9186396B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein modifiziertes Botulinumtoxin, das eine natürliche Schwere Kette und eine modifizierte Leichte Kette aufweist, dadurch gekennzeichnet, dass die Modifikation der Leichten Kette darin besteht, dass sie (i) an ihrem N-Terminus eine Verlängerung der Kette aufweist, die in der Richtung vom N- zum C-terminalen Ende die Struktur -(C)n-(tag)m-(X)l- hat, wobei C für einen Cystein-Rest, tag für einen beliebigen Tag und X für den Rest einer beliebigen natürlich vorkommenden Aminosäure stehen, n eine ganze Zahl von 1 bis 50, m 0 oder 1 und 1 0 oder eine ganze Zahl von 1 bis 50 ist, und dass (ii) wenigstens einer der Cystein-Reste in der Verlängerung der Kette an wenigstens eine Kette PEG gekoppelt ist.
PCT/EP2007/002296 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin Ceased WO2007104567A2 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP07723281A EP1994048B1 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin
HK09108510.5A HK1128929B (en) 2006-03-15 2007-03-15 Pegylated mutated clostridium botulinum toxin
US12/282,601 US8003601B2 (en) 2006-03-15 2007-03-15 Pegylated mutated clostridium botulinum toxin
DE502007001546T DE502007001546D1 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin
BRPI0708907-4A BRPI0708907A2 (pt) 2006-03-15 2007-03-15 toxina clostridium botulinum mutada por pegilação
CN200780015607.5A CN101432296B (zh) 2006-03-15 2007-03-15 聚乙二醇化的突变的肉毒梭菌毒素
AU2007224669A AU2007224669B2 (en) 2006-03-15 2007-03-15 Pegylated mutated clostridium botulinum toxin
MX2008011495A MX2008011495A (es) 2006-03-15 2007-03-15 Toxina de clostridium botulinum mutada pegilada.
KR1020087023540A KR101454273B1 (ko) 2006-03-15 2007-03-15 페그화된 돌연변이 클로스트리디움 보툴리눔 독소
CA002638862A CA2638862A1 (en) 2006-03-15 2007-03-15 Pegylated mutated clostridium botulinum toxin
AT07723281T ATE443078T1 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin
JP2008558725A JP5232021B2 (ja) 2006-03-15 2007-03-15 Ｐｅｇ化変異クロストリジウム・ボツリヌム毒素
IL193777A IL193777A (en) 2006-03-15 2008-08-31 Modified botulinum toxins and pharmaceutical compositions containing the same
US13/185,925 US8298550B2 (en) 2006-03-15 2011-07-19 PEGylated mutated Clostridium botulinum toxin
US13/624,493 US8912140B2 (en) 2006-03-15 2012-09-21 PEGylated mutated clostridium botulinum toxin
US14/538,132 US9186396B2 (en) 2006-03-15 2014-11-11 PEGylated mutated Clostridium botulinum toxin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06005300.6 2006-03-15
EP06005300A EP1834962A1 (de) 2006-03-15 2006-03-15 PEGyliertes mutiertes Clostridium botulinum Toxin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/282,601 A-371-Of-International US8003601B2 (en) 2006-03-15 2007-03-15 Pegylated mutated clostridium botulinum toxin
US13/185,925 Division US8298550B2 (en) 2006-03-15 2011-07-19 PEGylated mutated Clostridium botulinum toxin

Publications (2)

Publication Number Publication Date
WO2007104567A2 WO2007104567A2 (de) 2007-09-20
WO2007104567A3 true WO2007104567A3 (de) 2007-11-01

Family

ID=36603470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002296 Ceased WO2007104567A2 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin

Country Status (16)

Country Link
US (4) US8003601B2 (de)
EP (2) EP1834962A1 (de)
JP (1) JP5232021B2 (de)
KR (1) KR101454273B1 (de)
CN (1) CN101432296B (de)
AT (1) ATE443078T1 (de)
AU (1) AU2007224669B2 (de)
BR (1) BRPI0708907A2 (de)
CA (1) CA2638862A1 (de)
DE (1) DE502007001546D1 (de)
ES (1) ES2334283T3 (de)
IL (1) IL193777A (de)
MX (1) MX2008011495A (de)
RU (1) RU2426739C2 (de)
WO (1) WO2007104567A2 (de)
ZA (1) ZA200807284B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
CN102083451A (zh) 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
CA2727082C (en) 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
KR20110060903A (ko) 2008-08-29 2011-06-08 메르츠 파마 게엠베하 운트 코. 카가아 지속성이 변경된 클로스트리듐 신경독
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
EP2650003B1 (de) * 2010-05-20 2016-07-27 Allergan, Inc. Abbaubare clostridientoxine
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
KR102623475B1 (ko) 2014-11-07 2024-01-09 키네타 크로닉 페인, 엘엘씨 코노톡신 펩티드의 변형 및 용도
EP3590500B1 (de) 2014-12-23 2025-06-25 Merz Pharma GmbH & Co. KGaA Mit botulinumtoxin vorgefüllter behälter
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
WO2017181277A1 (en) 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
TWI822723B (zh) 2018-01-29 2023-11-21 英商艾普森生物製藥有限公司 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CN112165955A (zh) 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
EP4093434A4 (de) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologisch optimierte leichtkettenvarianten von botulinumtoxin
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
JP2025534349A (ja) 2022-09-30 2025-10-15 イプセン バイオファーム リミテッド 膀胱痛症候群の治療
CN116813727B (zh) * 2023-06-08 2025-06-06 苏州德进生物制药有限公司 一种a型肉毒毒素的制备方法及其应用
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074703A2 (de) * 1999-06-07 2000-12-14 Merz + Co. Gmbh & Co. Therapeutikum mit einem botulinum-neurotoxin
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074703A2 (de) * 1999-06-07 2000-12-14 Merz + Co. Gmbh & Co. Therapeutikum mit einem botulinum-neurotoxin
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHANTZ E J ET AL: "PROPERTIES AND USE OF BOTULINUM TOXIN AND OTHER MICROBIAL NEUROTOXINS IN MEDICINE", MICROBIOLOGICAL REVIEWS, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 56, no. 1, 1 March 1992 (1992-03-01), pages 80 - 99, XP000569909, ISSN: 0146-0749 *

Also Published As

Publication number Publication date
JP5232021B2 (ja) 2013-07-10
RU2426739C2 (ru) 2011-08-20
AU2007224669B2 (en) 2010-05-13
EP1994048A2 (de) 2008-11-26
BRPI0708907A2 (pt) 2011-06-21
IL193777A (en) 2011-09-27
CA2638862A1 (en) 2007-09-20
ZA200807284B (en) 2009-04-29
US9186396B2 (en) 2015-11-17
US8003601B2 (en) 2011-08-23
IL193777A0 (en) 2011-08-01
JP2009531026A (ja) 2009-09-03
HK1128929A1 (en) 2009-11-13
KR20080106451A (ko) 2008-12-05
US20110294747A1 (en) 2011-12-01
CN101432296A (zh) 2009-05-13
KR101454273B1 (ko) 2014-10-28
US8298550B2 (en) 2012-10-30
EP1994048B1 (de) 2009-09-16
US8912140B2 (en) 2014-12-16
US20090118193A1 (en) 2009-05-07
AU2007224669A1 (en) 2007-09-20
CN101432296B (zh) 2014-07-02
DE502007001546D1 (de) 2009-10-29
RU2008140368A (ru) 2010-04-20
WO2007104567A2 (de) 2007-09-20
ES2334283T3 (es) 2010-03-08
EP1834962A1 (de) 2007-09-19
US20150166977A1 (en) 2015-06-18
US20130156747A1 (en) 2013-06-20
ATE443078T1 (de) 2009-10-15
MX2008011495A (es) 2008-09-24

Similar Documents

Publication Publication Date Title
WO2007104567A3 (de) Pegyliertes mutiertes clostridium botulinum toxin
WO2005068494A3 (en) Chimera botulinum toxin type e
WO2010060821A3 (de) Wasch- und reinigungsmittel enthaltend proteasen aus bacillus pumilus
WO2007137329A3 (en) Multi-gene expression vehicle
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
WO2007148224A3 (en) Polypeptide
WO2008047363A3 (en) Method and system for content composition
NZ596295A (en) Anti-5T4 antibodies and uses thereof
PH12014500902A1 (en) Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2009137763A3 (en) Methods and compositions for the display of polypeptides on the pili of gram-positive bacteria
BRPI0606687A2 (pt) composições nutracêuticas
WO2008093058A3 (en) Peptides and their use
WO2008153429A3 (en) A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
TW200722436A (en) A peptide-immunoglobulin-conjugate
ATE435658T1 (de) Zusammensetzung mit mehreren botulinumtoxinen
WO2010057242A3 (de) Vakzin
WO2006135793A3 (en) Protein engineering with analogous contact environments
NO20070775L (no) Baerer for medikamenter for oppnaelse av oral biotilgjengelighet
EP1765374A4 (de) Zusammensetzungen, verfahren und verwendungen für eine neue familie von peptiden
WO2007110772A8 (en) Immunomodulating oligopeptides
ATE467643T1 (de) Peptide mit proliferationshemmender wirkung
WO2007101948A3 (fr) Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
WO2006122205A3 (en) Conus californicus neurotoxins
WO2007044115A3 (en) Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2010073015A3 (en) Peptide tag and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723281

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2638862

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 193777

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 7497/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/011495

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008558725

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007224669

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087023540

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008140368

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007723281

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007224669

Country of ref document: AU

Date of ref document: 20070315

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780015607.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12282601

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0708907

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080912